PDF(Pubmed)
Abstract：
Two new lanthanide-complexes based on the 5-nitropicolinate ligand (5-npic) were obtained and fully characterized. Single-crystal X-ray diffraction revealed that these compounds are isostructural to a Dy-complex, previously published by us, based on dinuclear monomers link together with an extended hydrogen bond network, providing a final chemical formula of [Ln2(5-npic)6(H2O)4]·(H2O)2, where Ln = Dy (1), Gd (2), and Tb (3). Preliminary photoluminescent studies exhibited a ligand-centered emission for all complexes. The potential antitumoral activity of these materials was assayed in a prostatic cancer cell line (PC-3; the 2nd most common male cancerous disease), showing a significant anticancer activity (50-60% at 500 μg·mL-1). In turn, a high biocompatibility by both, the complexes and their precursors in human immunological HL-60 cells, was evidenced. In view of the strongest toxic effect in the tumoral cell line provided by the free 5-npic ligand (~ 40-50%), the overall anticancer complex performance seems to be triggered by the presence of this molecule.
摘要：
获得了两种基于5-硝基吡啶甲酸配体（5-npic）的新镧系元素配合物，并对其进行了充分表征。单晶X射线衍射表明，这些化合物与Dy配合物同构，以前由我们出版，基于双核单体与扩展的氢键网络连接在一起，提供[Ln2（5-npic）6（H2O）4]·（H2O）2的最终化学式，其中Ln=Dy（1），Gd(2),Tb（3）。初步的光致发光研究显示，所有配合物都以配体为中心的发射。在前列腺癌细胞系（PC-3;第二常见的男性癌性疾病）中测定了这些材料的潜在抗肿瘤活性，显示出显着的抗癌活性（在500μg·mL-1时为50-60％）。反过来,两者的高生物相容性，人类免疫学HL-60细胞中的复合物及其前体，有证据。鉴于由游离5-npic配体（〜40-50％）提供的肿瘤细胞系中最强的毒性作用，整体抗癌复合物的性能似乎是由该分子的存在引发的。
